These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your RadarZacks Investment Research • 9h
Halozyme Therapeutics (HALO) Reports Next Week: Wall Street Expects Earnings GrowthZacks Investment Research • Thursday
How Halozyme, Up 80% This Year, Is Rivaling Merck And Hitting New HighsInvestors Business Daily • 10/23/26
5 Strong Buy Growth Stocks With High Margins to Grab Before EarningsZacks Investment Research • 10/21/26
3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO)Zacks Investment Research • 10/14/26
Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report?Zacks Investment Research • 10/13/26
Halozyme wins court order to block Merck's injected Keytruda in select European marketsReuters • 10/07/26
Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European MarketsPRNewsWire • 10/07/26
Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE® TechnologyPRNewsWire • 10/06/26
Strength Seen in Halozyme Therapeutics (HALO): Can Its 3.3% Jump Turn into More Strength?Zacks Investment Research • 09/23/26
Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033PRNewsWire • 09/18/26
Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033PRNewsWire • 09/16/26
Halozyme Therapeutics, Inc. (HALO) Presents at H.C. Wainwright 28th Annual Global Investment Conference TranscriptSeeking Alpha • 09/16/26
Halozyme Therapeutics, Inc. (HALO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/15/26